公开(公告)号：US20210251955A1

公开(公告)日：2021-08-19

申请号：US17242530

申请日：2021-04-28

Applicant: Yeda Research and Development Co. Ltd. ,  Memorial Sloan Kettering Cancer Center

Inventor： Liran SHLUSH ,  Omar ABDEL-WAHAB

IPC: A61K31/40 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4178 ,  A61K31/34 ,  A61K31/167 ,  A61K31/454 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/351 ,  A61K31/404 ,  A61K45/06 ,  A61P35/02

Abstract: A method of preventing a hematopoietic disorder or malignancy in a high risk subject, the subject being positive for one or more mutation in a splicing factor, is disclosed. The method comprising administering to the subject an agent capable of inhibiting spliceosomal activity, with the proviso that said agent does not inhibit RBM39 activity.

公开(公告)号：US20230364062A1

公开(公告)日：2023-11-16

申请号：US18134064

申请日：2023-04-13

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Liran SHLUSH ,  Tom FLEISCHER ,  Benjamin GEIGER ,  Minhua SU

IPC: A61K31/426 ,  C12Q1/6827 ,  A61P35/02

CPC classification number: A61K31/426 ,  C12Q1/6827 ,  A61P35/02

Abstract: A method is disclosed for treating or preventing a myeloid malignancy in a subject harboring a mutation in SRSF2 comprising:



(a) analyzing in a sample of the subject for the presence of an SRSF2 mutation; and
(b) administering to the subject a therapeutically effective amount of a Rho Kinase inhibitor, or an inhibitor of a downstream effector thereof, upon identification of SRSF2 mutation.